Neuphoria Therapeutics completes target enrollment in Phase 3 AFFIRM-1 trial

Neuphoria Therapeutics (NEUP) announced the achievement of target enrollment of 332 participants in the AFFIRM-1 Phase 3 trial evaluating lead candidate BNC-210 as a first-in-class, acute, “as needed”, fast-acting treatment for social anxiety disorder, SAD. “We are thrilled to reach our target enrollment in the AFFIRM-1 trial evaluating BNC-210 as a transformative therapeutic for the treatment of SAD,” said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Neuphoria. “Achieving this milestone puts us on a clear path toward our first Phase 3 data for BNC-210, now expected early in the fourth quarter.”